IEX •
Healthcare •
Biotechnology •
Quote as of 09/11/2026 15:59
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization18.11 mln
Float37.57 mln
Earnings Date11/18/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
1.52
Transformational upside
Relative Strength
97
/ 100
Top performer
ROA
-674
Deeply negative
Business Description
AEON Biopharma is a California-based medical research company working to bring new treatments to patients suffering from serious conditions such as cervical dystonia, chronic migraine, gastroparesis, and post-traumatic stress disorder. Its lead product, ABP-450, is an injectable botulinum toxin currently being tested in clinical trials, with one completed study and additional research still underway. The company works alongside partners Daewoong Pharmaceutical and Viatris to advance its pipeline toward potential approval.
